@article{ae980be835ca47c2b77162e7a7f95644,
title = "Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial",
abstract = "Sulodexide, a heterogenous group of sulfated glycosaminoglycans, includes low-molecular-weight heparin (~80% ± 8%), high-molecular-weight heparin (~5% ± 3%), and dermatan (~20% ± 8%), with a mean molecular weight of ~9 kDa. The drug is absorbed orally and has no anticoagulant effect in the doses used. Small preliminary studies consistently showed sulodexide to be associated with decreased albuminuria in patients with diabetes.",
keywords = "Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Glycosaminoglycans, Humans, Kidney Diseases, Male, Middle Aged",
author = "Lewis, {Edmund J} and Lewis, {Julia B} and Tom Greene and Hunsicker, {Lawrence G} and Tomas Berl and Pohl, {Marc A} and {de Zeeuw}, Dick and Heerspink, {Hiddo Lambers} and Rohde, {Richard D} and Atkins, {Robert C} and Reutens, {Anne T} and Packham, {David K} and Itamar Raz and Birger Thorsteinsson and Birger Thorsteinsson",
note = "deltagelse i study group",
year = "2011",
doi = "10.1053/j.ajkd.2011.06.020",
language = "English",
volume = "58",
pages = "729--36",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B.Saunders Co.",
number = "5",
}